POM-V Prescription Required

Triquest 333 mg/ml + 67 mg/ml Oral Suspension for Horses

Active ingredients: Sulfadiazine, Trimethoprim

Form

Liquid

Species

Horses

Manufacturer

Alfasan Nederland B.V.

VMD MA No.

36408/3039

What it's used for

Norodine 24 Injectable Solution is indicated in the treatment of systemic infections caused by or associated with organisms sensitive to the Trimethoprim:S...

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Sulfadiazine + Trimethoprim

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Triquest 333 mg/ml + 67 mg/ml Oral Suspension for Horses — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Norodine 24 Injectable Solution is indicated in the treatment of systemic
infections caused by or associated with organisms sensitive to the
Trimethoprim:Sulfadiazine combination. The spectrum of activity includes both
Gram-positive and Gram-negative organisms including:
Actinobacilli
Actinomycae
Bordetella spp
Brucella
Corynebacteria
Escherichia coli
Haemophilus spp
Klebsiella spp
Pasteurella spp

Revised: January 2026
AN: 03001/2025
Pneumococci
Proteus
Salmonella spp
Staphylococci
Streptococci
Vibrio

The recommended dose per administration is 30 mg of the active substances
together (i.e. 5 mg trimethoprim and 25 mg sulfadiazine) per kg bodyweight,
corresponding to 7.5 ml of the veterinary medicinal product per 100 kg bodyweight, 1
or 2 times per day. Frequency of dosing is decided on basis of the susceptibility of
the pathogens involved and location of the infection. Treatment should continue for
five days or until two days after the horse is free of symptoms up to a maximum of
five days.
Medication may be administered in the morning before offering the morning ration.
Similarly, when dosed twice daily the second dose may be administered before
providing the evening ration.
To ensure a correct dosage, body weight should be determined as accurately as
possible. One syringe is intended for up to 300 kg body weight and each syringe is
subdivided into 11 markings. The equivalent of one marking is sufficient to treat 25 kg
of body weight and the minimum body weight for treatment is 50 kg.
Before drawing up the dose in the syringe, the bottle should be shaken vigorously.
The veterinary medicinal product is administered orally by inserting the nozzle of the
syringe applicator through the interdental space and depositing the required amount
of veterinary medicinal product on the back of the tongue. Immediately after
administration, elevate the head of the horse for a few seconds to ensure the dose is
swallowed.
After administration of the veterinary medicinal product, close the bottle with the cap,
wash the syringe with water and let it dry.

Do not use in cases of hypersensitivity to the active substances or to any of the
excipients.
Do not use in animals with severe kidney or liver damage.

Horses:
Common
(1 to 10 animals / 100 animals
treated):
Digestive tract disorder (e.g. loose stool,
diarrhoea, colitis).
Undetermined frequency
(cannot be estimated from the
available data)
Hypersensitivity reaction (e.g. urticaria).
Inappetence.
Hepatic disorder.
Renal disorder, renal tubular disorder.
Haematologic effects (e.g. anaemia,
thrombocytopenia, or leucopenia), haematuria,
crystalluria.
tubular obstruction
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to
either the marketing authorisation holder or its local representative or the national
competent authority via the national reporting system. See the package leaflet for
respective contact details.

Cross-resistance has been shown between sulfadiazine and other sulfonamides. Use
of the veterinary medicinal product should be carefully considered when susceptibility
testing has shown resistance to sulfonamides because its effectiveness may be
reduced.
In case of infections involving purulent conditions, trimethoprim-sulfonamides
combinations are not recommended due to a diminished efficacy under such
conditions.

Special precautions for safe use in the target species:
Caution should be exercised when treating new-born animals and animals with liver
damage.
Renal impairment leads to risk of accumulation, increasing the risk of side effects in
long term treatment.
Throughout the treatment, animals should have free access to drinking water to avoid
possible crystalluria.
Use the veterinary medicinal product cautiously in horses with blood dyscrasias.
Use of the veterinary medicinal product should be based on identification and
susceptibility testing of the target pathogen(s). If this is not possible, therapy should
be based on epidemiological information and knowledge of susceptibility of the target
pathogens at farm level, or at local/regional level.
Use of the veterinary medicinal product should be in accordance with official, national
and regional antimicrobial policies.
Special precautions to be taken by the person administering the veterinary medicinal
product to animals:
This veterinary medicinal product contains sulfadiazine, a sulfonamide which can
cause hypersensitivity reactions following skin contact or accidental ingestion.
Hypersensitivity to sulfonamides may lead to cross reactions with other antibiotics.
Allergic reactions to sulfonamides may occasionally be serious. This veterinary
medicinal product may also cause skin or eye irritation.
Skin and eye contact with the veterinary medicinal product should be avoided. This is
especially important for people with known hypersensitivity to sulfonamides.
In the case of contact with skin, wash with soap and water. In the case of contact
with the eyes, wash with water.
If symptoms develop following exposure such as a skin rash or difficulty with
breathing and irritation persists, seek medical advice immediately and show the
package leaflet or the label to the physician.
Wash hands thoroughly after use.
Special precautions for the protection of the environment:
Not applicable.

Potentiated sulfonamides can cause fatal arrhythmias in horses sedated with alpha2-
adrenoceptor agonists.

This veterinary medicinal product does not require any special storage conditions.

Meat and offal: 20 days
Milk: Not authorised for use in animals producing milk for human consumption.
4.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.